Amiodarone Injection Shortage

• • Nexterone injection, Baxter, 360 mg/200 mL, premixed bag, 10 count, NDC 43066-0360-20
  • Amiodarone injection, Fresenius Kabi, 50 mg/mL, 3 mL vial, 10 count, NDC 63323-0616-03
  • Amiodarone injection, Fresenius Kabi, 50 mg/mL, 9 mL vial, 10 count, NDC 63323-0616-09
  • Amiodarone injection, Hikma, 50 mg/mL, 3 mL vial, 25 count, NDC 00143-9875-25
  • Amiodarone injection, Slate Run Pharmaceuticals, 50 mg/mL, 18 mL vial, 1 count, NDC 70436-0232-50
  • Amiodarone injection, Slate Run Pharmaceuticals, 50 mg/mL, 3 mL vial, 10 count, NDC 70436-0232-52
  • Amiodarone injection, Slate Run Pharmaceuticals, 50 mg/mL, 9 mL vial, 10 count, NDC 70436-0232-62

• • AuroMedics discontinued amiodarone in mid-2021.
  • Baxter has Nexterone premixed bags on shortage due to manufacturing delays.
  • Fresenius Kabi did not provide a reason for the shortage.
  • Hikma did not provide a reason for the shortage.
  • Viatris did not provide a reason for the shortage.
  • Sagent discontinued amiodarone 50 mg/mL 3 mL syringes in June 2019.
  • Slate Run Pharmaceuticals are launching amiodarone 3 mL, 9 mL, and 18 mL vials in March 2025.

• • Nexterone injection, Baxter, 150 mg/100 mL, premixed bag, 12 count, NDC 43066-0150-10
  • Amiodarone injection, Mylan Institutional (Viatris), 50 mg/mL, 18 mL vial, 10 count, NDC 67457-0153-18
  • Amiodarone injection, Mylan Institutional (Viatris), 50 mg/mL, 3 mL vial, 10 count, NDC 67457-0153-03
  • Amiodarone injection, Mylan Institutional (Viatris), 50 mg/mL, 9 mL vial, 10 count, NDC 67457-0153-09

Estimated Resupply Dates

• • Fresenius Kabi has amiodarone 50 mg/mL 3 mL and 9 mL vials on back order and the company cannot estimate a release date.
  • Hikma has amiodarone 50 mg/mL 3 mL vials on back order and the company estimates a release date of mid-May 2025.
  • Baxter has Nexterone 360 mg/200 mL premixes on allocation.
  • Slate Run Pharmaceuticals has amiodarone 3 mL, 9 mL, and 18 mL vials on allocation.